OMO Consultants

Executive Summary

OMO Consultants is a London-based consultancy serving the bio-pharmaceutical and medical device industries. Founded in 2015, the firm focuses on quality assurance, regulatory compliance, clinical services, and Qualified Person (QP) and Responsible Person (RP) services. By helping clients navigate complex regulatory landscapes, OMO enables faster market access for safe, effective products. The company occupies a niche role in a growing market driven by increasing regulatory demands and the need for specialized expertise. With no disclosed funding or revenue, OMO remains a private, bootstrapped operation, suggesting a steady but cautious growth trajectory. Its reputation and long-term relationships with clients in the highly regulated life sciences sector position it as a reliable partner, though scaling may require additional resources or strategic alliances. The UK life sciences consultancy market is expanding due to Brexit-driven regulatory changes and global harmonization efforts like the EU MDR and IVDR. OMO’s expertise in both QP and RP services is particularly valuable as these roles are mandatory for product release. The company is likely to benefit from pharmaceutical companies outsourcing non-core activities to reduce costs and ensure compliance. However, competition from larger consultancies and internal teams at big pharma poses risks. Overall, OMO is well-positioned in a resilient sector, but its lack of scale and visibility limits its near-term growth prospects. The conviction score reflects a balanced outlook given the stable demand but uncertain scalability.

Upcoming Catalysts (preview)

• Q3 2026Increased Demand for QP Services due to EU MDR/IVDR Implementation80% success
• H1 2027Expansion into EU Market via Strategic Partnership50% success
• H2 2026New Service Offering in Digital Health Compliance60% success